Research programme: MCL-1 protein inhibitors - Calithera BiosciencesAlternative Names: MCL-1 Program - Calithera Biosciences
Latest Information Update: 05 Nov 2013
At a glance
- Originator Calithera Biosciences
- Class Small molecules
- Mechanism of Action MCL1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)